MXPA04001187A - Receptores de interleucina-1 en el tratamiento de enfermedades. - Google Patents
Receptores de interleucina-1 en el tratamiento de enfermedades.Info
- Publication number
- MXPA04001187A MXPA04001187A MXPA04001187A MXPA04001187A MXPA04001187A MX PA04001187 A MXPA04001187 A MX PA04001187A MX PA04001187 A MXPA04001187 A MX PA04001187A MX PA04001187 A MXPA04001187 A MX PA04001187A MX PA04001187 A MXPA04001187 A MX PA04001187A
- Authority
- MX
- Mexico
- Prior art keywords
- interleukin
- receptors
- diseases
- treatment
- 1racp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invencion se refiere a metodos para el tratamiento de desordenes medicos caracterizados por niveles elevados o la expresion anormal de IL-1 mediante la administracion de un antagonista de IL-1, tal como receptor de IL-1 de tipo soluble y/o RacP IL-1. 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31078901P | 2001-08-07 | 2001-08-07 | |
PCT/US2002/024948 WO2003014309A2 (en) | 2001-08-07 | 2002-08-07 | Interleukin-1 receptors in the treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04001187A true MXPA04001187A (es) | 2004-07-08 |
Family
ID=23204113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04001187A MXPA04001187A (es) | 2001-08-07 | 2002-08-07 | Receptores de interleucina-1 en el tratamiento de enfermedades. |
Country Status (8)
Country | Link |
---|---|
US (1) | US20030049255A1 (es) |
EP (1) | EP1450837A4 (es) |
JP (1) | JP2005509597A (es) |
AU (1) | AU2002324625B2 (es) |
CA (1) | CA2456762A1 (es) |
MX (1) | MXPA04001187A (es) |
PL (1) | PL374118A1 (es) |
WO (1) | WO2003014309A2 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7771719B1 (en) * | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
DK1076703T4 (da) * | 1998-05-15 | 2011-03-28 | Genentech Inc | Terapeutiske anvendelser af IL-17-homologe polypeptider |
US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US20090035261A1 (en) * | 2000-03-21 | 2009-02-05 | Jian Chen | IL-17 homologous polypeptides and therapeutic uses thereof |
US7718397B2 (en) * | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
US20030203451A1 (en) * | 2000-08-24 | 2003-10-30 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US20030180255A1 (en) * | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US20030096969A1 (en) * | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
JP4875494B2 (ja) * | 2003-11-14 | 2012-02-15 | ユーシーエル バイオメディカ ピーエルシー | 免疫調節物質 |
EP1983000B1 (en) | 2003-11-21 | 2015-09-02 | UCB Biopharma SPRL | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
CA2607113C (en) * | 2004-05-05 | 2013-11-12 | Valorisation-Recherche, Societe En Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
JP2008542685A (ja) * | 2005-05-05 | 2008-11-27 | ヴァロリザーシヨン・アッシュエスジ,ソシエテ・アン・コマンディット | サイトカイン受容体修飾因子及びその使用 |
EP3332807B1 (en) | 2005-10-26 | 2023-02-22 | Novartis AG | Use of anti il-1beta antibodies |
US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
JP2009183176A (ja) * | 2008-02-05 | 2009-08-20 | Univ Of Tokyo | Il−1タイプiiレセプター遺伝子の欠損変異体マウス |
US20090317400A1 (en) | 2008-05-05 | 2009-12-24 | Krzysztof Masternak | Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof |
CA2725143A1 (en) * | 2008-05-21 | 2009-11-26 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
GB2472856B (en) * | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
JP5940093B2 (ja) | 2011-01-19 | 2016-06-29 | カンタージア アクチエボラーグ | 抗il−1rap抗体及びヒトを処置するためのそれらの使用 |
US9724409B2 (en) * | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
WO2014090800A1 (en) | 2012-12-10 | 2014-06-19 | Vib Vzw | Novel interleukin-33 inhibitors |
EP3313887A2 (en) | 2015-06-26 | 2018-05-02 | MAB Discovery GmbH | Monoclonal anti-il-1racp antibodies |
EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
US11248054B2 (en) | 2017-06-12 | 2022-02-15 | Bluefin Biomedicine, Inc. | Anti-IL1RAP antibodies and antibody drug conjugates |
US11633425B2 (en) | 2021-05-13 | 2023-04-25 | Ahava—Dead Sea Laboratories Ltd. | Anti-glycation compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989004838A1 (en) * | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5350683A (en) * | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
WO1991018982A1 (en) * | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
EP1239043A3 (en) * | 1992-03-30 | 2003-01-02 | Immunex Corporation | Fusion proteins comprising tumour necrosis factor receptor |
PE64396A1 (es) * | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
NZ322197A (en) * | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
US5843904A (en) * | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
ATE244234T1 (de) * | 1997-04-24 | 2003-07-15 | Ortho Mcneil Pharm Inc | Substituierte imidazole zur behandlung von entzündlichen krankheiten |
AU2001259758A1 (en) * | 2000-05-12 | 2001-11-26 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
WO2002064630A2 (en) * | 2000-10-31 | 2002-08-22 | Immunex Corporation | Il-1 receptor accessory protein |
-
2002
- 2002-08-07 EP EP02759279A patent/EP1450837A4/en not_active Withdrawn
- 2002-08-07 PL PL02374118A patent/PL374118A1/xx not_active Application Discontinuation
- 2002-08-07 AU AU2002324625A patent/AU2002324625B2/en not_active Ceased
- 2002-08-07 US US10/215,211 patent/US20030049255A1/en not_active Abandoned
- 2002-08-07 JP JP2003519439A patent/JP2005509597A/ja active Pending
- 2002-08-07 CA CA002456762A patent/CA2456762A1/en not_active Abandoned
- 2002-08-07 MX MXPA04001187A patent/MXPA04001187A/es not_active Application Discontinuation
- 2002-08-07 WO PCT/US2002/024948 patent/WO2003014309A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2003014309A2 (en) | 2003-02-20 |
US20030049255A1 (en) | 2003-03-13 |
EP1450837A2 (en) | 2004-09-01 |
EP1450837A4 (en) | 2006-01-04 |
CA2456762A1 (en) | 2003-02-20 |
WO2003014309A3 (en) | 2004-06-24 |
PL374118A1 (en) | 2005-10-03 |
AU2002324625B2 (en) | 2008-05-08 |
JP2005509597A (ja) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
EP2329842A3 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
GB0222495D0 (en) | Compounds | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
BRPI0518228A (pt) | inibidores de cinesina mitótica e métodos de uso destes | |
TW200611695A (en) | Pyrrolopyridine derivatives | |
TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
TNSN07161A1 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
TW200612926A (en) | Compounds and compositions as ppar modulators | |
HUP0102511A2 (hu) | Kombinált gyógykezelés bipoláris betegségek kezelésére | |
RS20050344A (en) | Treatment for hemorrhagic shock | |
MXPA05008438A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6. | |
IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
TW200510367A (en) | Novel lapachone compounds, their preparation, and the use thereof | |
AU5338401A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
MXPA05011432A (es) | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. | |
AU2003260436A1 (en) | Pyrimidine compounds | |
EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
WO2000076500A8 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
TNSN06382A1 (en) | Compounds and compositions as ppar modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |